Bloom Science, Inc.

Bloom Science, Inc. is a biopharma and biotechnology company leveraging the Gut-Brain Axis to drive therapeutic innovation. Founded in 2018, the company is focused on developing transformative therapeutics for patients with rare and complex neurological disorders. Bloom Science's proprietary discovery platform, IrisRx™, allows for a unique approach to developing medicines by harnessing insights into the Gut-Brain Axis. This enables the design and development of therapeutics that target novel biology with superior safety profiles. The company is working on a deep pipeline of programs, including those for Dravet syndrome, other rare epilepsies, Amyotrophic Lateral Sclerosis (ALS), and neurodegenerative and cognitive disorders. In December 2021, Bloom Science secured a $12.00M Series A investment from notable investors including Joyance Partners, Apollo Health Ventures, ALS Investment, and Leaps by Bayer. The company's mission-driven culture is centered around empowering its team members to approach every clinical trial with the understanding that a patient's life depends on it. Bloom Science's dedication to advancing science and potentially transforming medicine is evident in its commitment to addressing challenging neurological conditions. For more information, visit Bloom Science's website.